# Similar Perceptions on Continuous Glucose Monitor Use amongst Youth with Type 1 and Type 2 Diabetes

**Authors:** Alexander Phu, Tyger Lin, Jacquelyn A. Manfredo, Elizabeth A. Brown, Risa M. Wolf

PMC · DOI: 10.1155/2023/1979635 · Pediatric Diabetes · 2023-06-19

## TL;DR

Youth with type 1 and type 2 diabetes have similar views on using continuous glucose monitors and report similar quality of life.

## Contribution

The study reveals similar perceptions of CGM use and diabetes-related distress in youth with T1D and T2D on insulin therapy.

## Key findings

- Youth with T1D and T2D scored similarly on CGM benefit and burden questionnaires.
- Female youth had higher odds of diabetes-related distress, particularly regimen-related distress.
- CGM use may help improve quality of life for both T1D and T2D youth on insulin.

## Abstract

Youth with T1D and T2D (currently on insulin therapy) without current CGM participated in a prospective CGM study and were given a series of questionnaires when starting CGM intervention. BenCGM and BurCGM questionnaires assessed the participant's perspectives on continuous glucose monitor use, while DDS surveys assessed participants' QoL associated with diabetes. Survey results were compared between T1D and T2D groups, and multivariable analysis was used to assess differences in perceptions of continuous glucose monitor use in youth with diabetes.

Participants with T1D (n = 26, 65.4% male, 42.3% non-Hispanic black, median age 14.2 years, median HbA1c 10.3%) and T2D (n = 41, 39% male, 80.5% non-Hispanic black, median age 16.2 years, median HbA1c 10.3%) scored similarly on the BenCGM, BurCGM, and DDS surveys. In a pooled analysis of both T1D and T2D, there was no difference in survey results by race/ethnicity, but female youth had an increased odd of diabetes-related distress, specifically regimen-related distress.

Youth with T1D and T2D on insulin therapy report similar perspectives on continuous glucose monitor use and QoL measures. Insulin use in both T1D and T2D may carry a similar burden of management, and CGM may help improve quality of life. Trial registration: This trial is registered with NCT04721145, NCT04721158.

## Linked entities

- **Diseases:** Type 1 diabetes (MONDO:0005147), Type 2 diabetes (MONDO:0005148)

## Full-text entities

- **Genes:** INS (insulin) [NCBI Gene 3630] {aka IDDM, IDDM1, IDDM2, ILPR, IRDN, MODY10}
- **Diseases:** T2D (MESH:D003924), diabetes (MESH:D003920), T1D (MESH:D003922)
- **Chemicals:** Continuous Glucose Monitor (-)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12017215/full.md

## References

23 references — full list in the complete paper: https://tomesphere.com/paper/PMC12017215/full.md

---
Source: https://tomesphere.com/paper/PMC12017215